PERSONALIS ($NASDAQ:PSNL) announced their financial results for the second quarter of the fiscal year 2023 (ending on August 8th) on June 30th 2023. Total revenue for Q2 amounted to USD 16.7 million, showing a drop of 8.4% compared to the same period in the previous year. The reported net income was USD -24.0 million, lower than the -27.6 million recorded a year ago.
On Tuesday, PERSONALIS, a global leader in providing personalised healthcare solutions, released its Q2 earnings results for the fiscal year ending August 8th, 2023. The report showed that the company’s stock opened at $1.9 and closed at $2.0, representing a 4.2% increase from the previous closing price of $1.9. This performance was achieved despite increased expenses and investments in research and development, as well as marketing and sales initiatives. This was mainly due to cost-cutting efforts and a decrease in working capital requirements.
Overall, PERSONALIS reported a successful quarter with its stock increasing by 4.2% from the previous closing price of $1.9. The company’s strong financial performance and cash flow growth demonstrate that it is well-positioned to take advantage of future growth opportunities and continue to deliver value for its shareholders. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Personalis. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Personalis. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Personalis. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Personalis are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
GoodWhale conducted an analysis of PERSONALIS‘s wellbeing and based on our Star Chart, we concluded that PERSONALIS has an intermediate health score of 4/10 with regard to its cashflows and debt. We have classified PERSONALIS as an ‘elephant’, a type of company that has rich assets after deducting off liabilities. Given the strengths in asset, medium growth and weak dividend and profitability, we believe that certain types of investors may find PERSONALIS appealing. For example, long-term, value-focused investors may find potential opportunities by investing in PERSONALIS, as there is potential for them to benefit from the company’s asset-rich base. As well, investors who are focused on growth may be interested in the company’s medium growth rate, which may offer them some potential upside. Finally, investors who are looking for a steady dividend yield may not find PERSONALIS appealing, given its weak dividend yield. Overall, our analysis depicts a company with an intermediate health score and potential appeal to various types of investors. Given its rich assets and medium growth, we believe that PERSONALIS is in a strong position to sustain future operations in times of crisis. More…
Risk Rating Analysis
Star Chart Analysis
Personalis Inc is a leading provider of precision medicine solutions. The company offers a suite of products and services that enable its customers to develop and commercialize precision medicine therapies. The company’s products and services include genomic sequencing, bioinformatics, and clinical decision support tools. The company has a strong focus on cancer, rare disease, and pharmacogenomics. Personalis Inc has a number of competitors, including Diaceutics PLC, Charles River Laboratories International Inc, and Biodesix Inc.
– Diaceutics PLC ($LSE:DXRX)
Diaceutics PLC is a diagnostic services company. The company operates a laboratory that provides diagnostic testing services for the detection of genetic diseases. The company also manufactures and sells diagnostic kits and products. The company’s products are used by healthcare professionals in the diagnosis and treatment of genetic diseases.
– Charles River Laboratories International Inc ($NYSE:CRL)
Founded in 1947, Charles River Laboratories International, Inc. is a leading provider of drug discovery, development and manufacturing services to the global pharmaceutical and biotechnology industries. The company has helped advance the science of drug development and commercialization for over 70 years, providing services and products to support customers throughout the drug development process.
Charles River Laboratories International, Inc. has a market cap of $10.47B as of 2022 and a Return on Equity of 13.86%. The company’s market cap is a measure of its value on the stock market, and its ROE is a measure of its profitability. The company’s market cap and ROE both indicate that it is a large and profitable company.
Biodesix Inc is a biotechnology company that develops and commercializes blood-based molecular diagnostic tests for the early detection and treatment of cancer. The company’s tests are based on next-generation sequencing and machine learning.
Biodesix’s market cap is 45.58M as of 2022. The company has a Return on Equity of -655.98%. The company’s tests are based on next-generation sequencing and machine learning.
PERSONALIS reported their earnings results for the second quarter of FY2023 on June 30, 2023. Total revenue decreased 8.4% year over year, coming in at USD 16.7 million. Net income also decreased, coming in at -24.0 million compared to -27.6 million the previous year. Despite the lower revenue and income, the stock price moved up the same day.
Investors may want to consider that despite the lower revenues and income, the stock is clearly being perceived positively by the market. They should also take into account the company’s history of performance and outlook for the future. Overall, PERSONALIS may present an opportunity for investors to capitalize on a potentially undervalued stock.